MedTrace Logo

Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation

NCT02669940 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 158

Last updated 2018-11-14

Study results available
· View outcomes & findings →

Summary

This study seeks to assess the effectiveness, patient reported outcomes, work productivity and healthcare resource utilization of the interferon-free regimen of paritaprevir /ritonavir (r) - ombitasvir, ± dasabuvir ± ribavirin (RBV) in participants with chronic hepatitis C in a real life setting across clinical practice populations.

Conditions

  • Chronic Hepatitis C
  • Genotype 1

Sponsors & Collaborators

Principal Investigators

  • Andrey Strugovschikov, MD · AbbVie

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-15
Primary Completion
2017-07-04
Completion
2017-07-04

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02669940 on ClinicalTrials.gov